Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Vulvar cancer (VC) accounts for <1% of cancers affecting the female gender. Clinical Pathways (CP) and Clinical Outcomes Monitoring are useful for providing high-quality care to these patients. However, it is essential to integrate them with the patient's perspective according to Value-Based Healthcare paradigms. Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) are tools for assessing outcomes and experiences with health care from the patient's perspective. The aim of this paper is to collect and synthesize PROMs and main stakeholders' experience on the VC CP, according to a value-based approach.

Materials And Methods: To select the most appropriate instrument, a review was conducted on the main databases and official websites of specific institutions and organizations. In the second phase, a 2-round Delphi survey was conducted to assess the Reported Experience Measures (REMs) tool. Questions were evaluated according to four criteria (general relevance, evidence-based, measurability, actionability) and included if strong agreement was reached. A Principal Component Analysis (PCA) was executed. Cronbach's alpha and McDonald's omega were computed. Fisher's exact test and Wilcoxon rank sum test were used to compare ratings between groups. Descriptive statistics were performed for both PROMs and REMs instruments.

Results: For PROMs assessment, EORTC QLQ-C30 questionnaire was selected and administered to 28 patients. Global Health Status/Quality of Life and Functional Scales Scores were high or very high, while symptoms scale reported low or medium scores. The final REMs consists of 22 questions for professionals and 16 for patients and caregivers. It was administered to 22 patients, 11 caregivers, 5 physicians, 2 nurses and 1 clinical senior manager. PCA identified 4 components. Scale reliability was acceptable (α = 0.75 95% CI: 0.61-0.85; ω = 0.69; 95% CI: 0.54, 0.82). A statistically significant difference between the patient/caregiver group and the professionals was found for items 8 (follow-up), 10 (perceived quality), 12 (safety), and 16 (climate) ( = 0.02; = 0.03; < 0.001; < 0.001, respectively).

Discussion: PROMs could provide new ways of intercepting patients' needs and feedback, thus acting on them. The proposed REMs tool would allow to detect information not available elsewhere, which, through Audit and feedback strategies, could lead to enhancement of healthcare experience, according to a value-based approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807601PMC
http://dx.doi.org/10.3389/fpubh.2022.1014651DOI Listing

Publication Analysis

Top Keywords

vulvar cancer
8
gov➔value combine
4
combine reported
4
reported quality
4
quality experiences
4
experiences patient-reported
4
patient-reported outcome
4
outcome measures
4
measures vulvar
4
cancer patients
4

Similar Publications

Immune checkpoint inhibitors in gynecologic oncology: Current status and perspectives.

Int J Gynaecol Obstet

September 2025

Department of Obstetrics and Gynecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by leveraging the immune system's capacity to fight gynecologic cancer. This review summarizes the current status and future perspectives of ICIs in the treatment of cervical, endometrial, and ovarian cancers and rare tumors. ICIs have demonstrated significant efficacy in tumors with high tumor mutational burden and immune markers such as PD-L1 expression and microsatellite instability.

View Article and Find Full Text PDF

Background: The development of antibody-drug conjugates (ADC) for cancer treatment has achieved promising results in different solid tumors and targets. Enfortumab-Vedotin (EV), a humanised anti-Nectin4-IgG1 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE), is an FDA-approved Nectin4-directed ADC for the treatment of locally advanced or metastatic pre-treated urothelial cancer. Targeted therapy with EV requires the expression of Nectin4 within the tumor cells.

View Article and Find Full Text PDF

Objectives: To assess histologic changes in the peritoneal neovagina following RPGAV to better guide shared decision-making regarding vaginoplasty techniques. Robotic-Assisted Peritoneal Flap Gender-Affirming Vaginoplasty (RPGAV) uses pedicled flaps of pelvic peritoneum to form the proximal neovagina. Early reports of peritoneal vaginoplasty suggested potential for "self-lubrication"; however, long-term maintenance of fluid production remains uncertain.

View Article and Find Full Text PDF

Rectal melanoma is an extremely rare and highly aggressive disease, and rectal melanoma metastasis to the breast is rare. This is a 48-year-old female who presented with rectal melanoma carcinoma Following the diagnosis of locally advanced rectal cancer (TxN3M0), she received chemotherapy, immunotherapy with radiotherapy, and metastases to the lung, bone and vulvar developed during the therapy. After one year of treatment, the patient developed bilateral breast metastases.

View Article and Find Full Text PDF

Inguinofemoral lymphadenectomy remains a critical component of staging and treatment for vulvar and penile squamous cell carcinoma. Traditionally performed via an open approach, this procedure is associated with significant morbidity, including lymphocyst formation, chronic lymphedema, and delayed recovery. A minimally invasive alternative, via laparoscopic or robotic platforms, is gaining traction as it is associated with a lower risk of surgical morbidity.

View Article and Find Full Text PDF